Drug discovery teams are under increasing pressure to accelerate timelines without compromising data quality. Yet many labs still rely on LC–MS workflows that take minutes per sample, require significant cleanup, and struggle with complex matrices. As biological questions shift toward intact proteins, covalent binders, and real‑time cell‑based assays, the limitations of chromatographic throughput have become impossible to ignore, driving labs to explore high-throughput MS approaches.

Explore amyotrophic lateral sclerosis drug discovery with patient-derived iPSC organoids, highlighting advances, challenges, and their role in replicating ALS phenotypes